Biotech boosted in priority plan: CSIRO
01 February, 2006 by Ruth BeranCSIRO's biotechnology and life science programs will be strengthened, the organisation claimed yesterday in the launch of its research policies for 2006/07 and beyond.
In brief: Acrux, Proteome Systems, Panbio, Virax
31 January, 2006 by Staff WritersRoss Dobinson has been appointed as Acrux's (ASX:ACR) non-executive chairman, replacing Nuno D'Aquino who is stepping down due to private commitments. D'Aquino will continue as a non-executive director and will chair the board's Human Capital Committee.
WA minister cops flak from prestigious journal
31 January, 2006 by Graeme O'NeillInternational science journal Nature Biotechnology has taken the Western Australian agriculture minister Kim Chance to task for funding a supposedly independent study of the health effects of genetically modified food crops by an Adelaide research institute renowned for its anti-GM activism.
Sirtex posts positive net cash flow
31 January, 2006 by Ruth BeranSydney biomedical company Sirtex Medical (ASX:SRX) has posted a positive net cash flow for the second quarter of 2005/06 of AUD$1.46 million, an increase of 87 per cent on the previous quarter.
New $35m biotech VC fund launched in SA
30 January, 2006 by Graeme O'NeillSouth Australia's rapidly expanding biotechnology industry now has access to AUD$35 million in venture capital, with Bio Innovation SA securing a deal with one of Australia's most successful superannuation funds, MTAA Super.
In brief: Eqitx, Chemeq, NeuroSolutions
30 January, 2006 by Staff WritersMelbourne-based Eqitx (ASX:EQX) has invested a further AUD$500,000 in equity in VacTX, making its total investment in the vaccine developer $2.3 million to date.
Norwood Abbey to test virosomal delivery
27 January, 2006 by Ruth BeranNorwood Abbey (ASX:NAL) has initiated animal studies for the use of its needle-free injection device for delivering virosomes, potent carriers of antigens for vaccination.
BresaGen executes supply contracts
27 January, 2006 by Helen SchullerAdelaide biotechnology manufacturer BresaGen (ASX:BGN) has executed supply contracts worth AUD$680,000 with WA based junior biotech Caldeon and Brisbane's Tissue Therapies (ASX:TIS).
Virax sanguine on shortfall in $3.1m raising
23 January, 2006 by Helen SchullerMelbourne immunotherapy developer Virax Holdings (ASX:VHL) has raised $3.1 million through a rights issue for the further development of its HIV therapeutic vaccine, falling $700,000 short of the $3.8 million the company planned to raise.
LCT to raise additional US and European capital
23 January, 2006 by Helen SchullerFollowing the successful placement of more than AUD$3 million worth of shares in the US earlier this month, cell therapy company Living Cell Technologies (ASX:LCT) has revealed plans to raise at least a further AUD$8 million through a second tranche of shares in the US and Europe.
Ellex sells property for $4.43m
20 January, 2006 by Helen SchullerAdelaide company Ellex Medical Lasers (ASX:ELX) has signed a contract for the sale of its building in Adelaide for a price of $4.43 million.
Infertility expert appointed Victorian governor
19 January, 2006 by Graeme O'NeillThe Victorian premier, Steve Bracks, has appointed renowned Melbourne endocrinologist Prof David de Kretser, AO, to succeed John Landy as the state's governor.
Clover cancels AIM listing
19 January, 2006 by Ruth BeranSydney-based Clover (ASX:CLV) has applied to the London Stock Exchange to cancel its listing on the Alternative Investment Market (AIM).
New CEO and President for Novogen's US subsidiary
18 January, 2006 by Ruth BeranSydney-based biopharma Novogen's (ASX:NRT, Nasdaq:NVGN) US subsidiary, Glycotex, has appointed Dr Reinhard Koenig as CEO and president.
Phosphagenics delivers further positive morphine results
18 January, 2006 by Ruth BeranA phase Ib clinical trial of Melbourne-based Phosphagenics' (ASX:POH, AIM:PSG) TPM-01 transdermal delivery system has demonstrated that therapeutic levels of morphine in plasma were achieved and maintained for more than 48 hours using the technology.
